Aligos Therapeutics, Inc. ALGS
4.75 USD +0.15 (+3.26%)
At closeNov 3, 2026, 4:02 PM EST
4.75 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
4.65 Day range 4.95
3.98 52-week range 13.69
- YTD
- -49.03%
- 1 year
- -36.92%
Analyst view
Price target (mean) 103.33 +2075.4% upside
Now 4.75
- Target (low)
- 60.00
- Target (mean)
- 103.33
- Target (high)
- 175.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -3.67 | -3.67 – -3.67 | -5.50 | +33.3% | 433.33K | -78.4% | 1 |
| Next quarter | -3.04 | -4.22 – -1.85 | -5.50 | +44.8% | 333.33K | -66.2% | 2 |
| Current year | -10.36 | -11.51 – -9.21 | -34.00 | +69.5% | 3.74M | -59.9% | 2 |
| Next year | -13.01 | -17.88 – -8.13 | -10.36 | -25.5% | 2.00M | -46.6% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Jan 17, 2023 | Piper Sandler | Maintained | — | Overweight |
| Jan 6, 2023 | Piper Sandler | Upgrade | Neutral | Overweight |
| Jan 6, 2023 | Jefferies | Upgrade | Hold | Buy |
| Nov 3, 2022 | SVB Leerink | Maintained | — | Market Perform |
| May 5, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Mar 23, 2022 | SVB Leerink | Maintained | — | Outperform |
| Mar 23, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Mar 11, 2022 | Piper Sandler | Maintained | — | Overweight |
| Mar 11, 2022 | SVB Leerink | Maintained | — | Outperform |
| Feb 16, 2022 | SVB Leerink | Maintained | — | Outperform |
| Jan 7, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Jan 7, 2022 | SVB Leerink | Maintained | — | Outperform |
| Sep 9, 2021 | SVB Leerink | Initiated | — | Outperform |
| Nov 10, 2020 | Jefferies | Initiated | — | Buy |
| Nov 10, 2020 | JP Morgan | Initiated | — | Overweight |
| Nov 10, 2020 | Piper Sandler | Initiated | — | Overweight |